Zoetis (NYSE:ZTS) Earns Buy Rating from Analysts at Citigroup

Citigroup assumed coverage on shares of Zoetis (NYSE:ZTS) in a report published on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $145.00 price target on the stock.

A number of other brokerages have also recently commented on ZTS. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. Finally, Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Hold” and an average price target of $152.25.

Zoetis Stock Up 2.8%

Shares of ZTS opened at $122.39 on Wednesday. Zoetis has a 52 week low of $113.29 and a 52 week high of $172.23. The stock has a market capitalization of $51.48 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.82 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a fifty day moving average of $121.73 and a 200-day moving average of $126.50.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the company earned $1.40 EPS. Zoetis’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts anticipate that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZTS. Summit Place Financial Advisors LLC grew its stake in shares of Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the period. First County Bank CT grew its stake in shares of Zoetis by 5.4% in the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock valued at $225,000 after buying an additional 79 shares during the period. CWA Asset Management Group LLC grew its stake in shares of Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after buying an additional 80 shares during the period. RFG Advisory LLC grew its stake in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. Finally, YANKCOM Partnership grew its stake in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after buying an additional 81 shares during the period. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.